

OMB APPROVAL	
OMB Number:	3235-0116
Expires:	December 31, 2026
Estimated average burden hours per response	8.7

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of September, 2025.

Commission File Number 001-41670

---

**Apollomics, Inc.**  
(Translation of registrant's name into English)

---

989 E. Hillsdale Blvd., Suite 220, Foster City, California 94404  
(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       Form 40-F

---

---

## Press Releases

On September 22, 2025, Apollomics Inc. (“Apollomics” or the “Company”) issued a press release announcing its receipt of a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that unless the Company requests an appeal, Nasdaq will delist the Company’s securities under Nasdaq Listing Rule 5101 based on the Staff’s belief that Apollomics is now only a “public shell”. As discussed in greater detail in the press release, the Company disagrees with the Staff and will appeal. The press release also provides certain updates with respect to the Company’s ongoing operations.

On September 25, 2025, Apollomics issued another press release announcing its completion of the filing of its application on September 23, 2025 to appeal the delisting notification it had earlier received from the Staff of Nasdaq. Additionally, Apollomics announced that in connection with the Writ and Statement of Claim issued in the Grand Court of the Cayman Islands by one investment manager for two minority investors in the Company dated July 22, 2024 (the “Cayman Litigation”), the Grand Court of the Cayman Islands has issued a consent order via consent of all parties that all further steps in these proceedings of the Cayman Litigation are stayed from and after September 12, 2025, until further order from such court.

The press releases are attached here as Exhibit 99.1 and 99.2.

## EXHIBITS

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press Release - Apollomics Announces Receipt of Delisting Determination Letter from Nasdaq</a>
99.2	<a href="#">Press Release - Apollomics Announces Completion of Filing of Appeal of Nasdaq Delisting Order</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date September 25, 2025

\_\_\_\_\_  
/s/ Peter Lin

(Signature)\*

Peter Lin, Chief Financial Officer

\* Print the name and title under the signature of the signing officer.

SEC 1815 (07-22)

Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

PRESS RELEASE

**Apollomics Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain Nasdaq Listing**

By: **Apollomics Inc. (Nasdaq: APLM)**

Via: Global Bio and Investment

Date: September 21, 2025

Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that the Company received a letter (the “Letter”) on September 18, 2025 from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”).

The Letter indicated that unless the Company requests an appeal, Nasdaq will delist the Company’s securities under Nasdaq Listing Rule 5101 based on the Staff’s belief that Apollomics is now only a “public shell”. The Letter stated that the Staff believe the Company no longer has an operating business, citing a lack of personnel and uncertainty around staffing initiatives, and this could lead to the Company’s shares being subject to market abuses and other violative conduct as purchasers of a public shell do not know what the operating business will be in the future.

Other than as identified above, the Company believes it is in compliance with the Nasdaq listing requirements set forth in Nasdaq Listing Rule 5550.

The Company will appeal. The Company’s management strongly believes that Apollomics is not a public shell and remains an operating clinical-stage pharmaceutical company. Apollomics continues to be focused on the discovery and development of oncology therapies. These therapies have the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

Apollomics historically and continues to use targeted, immuno-oncology, and other innovative approaches to address a range of cancer indications, such as lung cancer, brain cancer, and other solid tumors. The Company’s pipeline includes a variety of cancer treatment programs that utilize tumor inhibitors, immune checkpoint inhibitors, a cancer vaccine, monotherapies, combination therapies or a multi-functional protein with the goals to improve response rates and reduce chemo-resistance and toxicity compared to the current treatment standards.

The Company announced on August 28, 2025, that it intended to seek shareholder approval to wind up the Company’s business, and that it expected to discontinue all activities related to the SPARTA clinical trials associated with vebreltinib, our most advanced product candidate. However, on September 3, 2025, the Company received \$4.1 million in a private placement and appointed a new board of directors.

With additional funding, the Company reversed its wind-up plans. It is continuing previous operations and is actively expanding operations focused on advancing the global development and achieving the full potential of vebreltinib.

Among other initiatives, Apollomics seeks to develop vebreltinib across different c-Met alterations across different tumors; developing other tumor inhibitor candidates; expand our drug portfolio through collaboration and partnership; seek development and commercialization partnerships to optimize efficiency; and build a network of centers for clinical trials. Current clinical trials include: trials of vebreltinib as a single agent for the potential treatment of NSCLC and other advanced tumors with c-Met alterations, and also as a combination therapy with epidermal growth factor receptor inhibitors (the “SPARTA studies”).

The Company is preparing to file a notice of appeal on or prior to September 25, 2025, and will request a hearing before a Nasdaq Listing Qualifications Panel to review the Staff’s determination. The appeal, when filed, will stay delisting of the Company’s securities pending the Panel’s decision. Unless the Company requests an appeal, trading in the Company’s securities will be suspended at the opening of business on September 29, 2025, and a Form 25-NSE will be filed with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on The Nasdaq Stock Market. Although the Company believes that it will prevail in its appeal, there is no guarantee that the Company will be able to win its appeal, or will regain or maintain its Nasdaq listing.

\*\*\*\*\*

#### **About Apollomics Inc.**

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit [www.apollomicsinc.com](http://www.apollomicsinc.com).

#### **Cautionary Statement Regarding Forward-Looking Statements**

This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, or the appeal of, response to, or outcome of the NASDAQ Letter, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-

looking statements contain such identifying words. These forward-looking statements are based on management's current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics' operations and the continued listing of Apollomics' securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics' oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics' intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission ("SEC") under the heading "Risk Factors" and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC's website at [www.sec.gov](http://www.sec.gov). Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

**Investor Contacts:**

Peter Lin, Chief Financial Officer  
Apollomics, Inc.  
Phone: 1-650-209-4055  
Email: [peter.lin@apollomicsinc.com](mailto:peter.lin@apollomicsinc.com)



## Apollomics Announces Completion of Filing of Appeal of Nasdaq Delisting Order

Apollomics Inc. (NASDAQ:APLM APLMW)

FOSTER CITY, CA, UNITED STATES, September 25, 2025/[EINPresswire.com/](https://www.einpresswire.com/) - Appeal of Nasdaq Delisting Order Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced that on September 23, 2025 the Company has completed the filing of its application to appeal the delisting notification previously received from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) and request a hearing before a Nasdaq Hearings Panel to review the Staff’s determination. Although the Company believes that it will prevail in its appeal, there is no guarantee that the Company will be able to win, or will regain or maintain its Nasdaq listing.

### Stay Notice of the Cayman Litigation

As previously disclosed, on July 22, 2024, the Company received a copy of a Writ and Statement of Claim filed in the Grand Court of the Cayman Islands by an investment manager for two minority investors in the Company (the “Cayman Litigation”).

Upon joint application of the parties, the Grand Court of the Cayman Islands has issued a consent order that all further proceedings of the Cayman Litigation would be stayed from and after September 12, 2025, until further order.

### About Apollomics Inc.

Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit [www.apollomicsinc.com](http://www.apollomicsinc.com).

### Cautionary Statement Regarding Forward-Looking Statements

This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib, future proceedings with respect to the Cayman Litigation, or the appeal of, response to, or outcome of the Nasdaq delisting notification, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

Peter Lin  
Apollomics Inc.  
+1 650-209-4055  
[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/852261836/>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2025 Newsmatics Inc. All Right Reserved.